| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/23/2022 | 5.32% | Piper Sandler | $135 → $150 | Maintains | Neutral |
| 09/15/2022 | 15.85% | Wolfe Research | → $165 | Upgrades | Peer Perform → Outperform |
| 09/14/2022 | 44.64% | Loop Capital | → $206 | Initiates Coverage On | → Buy |
| 09/12/2022 | 20.77% | Stifel | $162 → $172 | Maintains | Buy |
| 08/10/2022 | 25.68% | Needham | $163 → $179 | Maintains | Buy |
| 08/10/2022 | -5.21% | Piper Sandler | $130 → $135 | Maintains | Neutral |
| 05/04/2022 | 14.45% | Needham | $205 → $163 | Maintains | Buy |
| 04/06/2022 | 12.34% | Wolfe Research | → $160 | Initiates Coverage On | → Peer Perform |
| 03/31/2022 | 22.88% | Stifel | $250 → $175 | Maintains | Buy |
| 03/17/2022 | 12.34% | Piper Sandler | $200 → $160 | Maintains | Neutral |
| 02/18/2022 | 43.94% | Needham | → $205 | Upgrades | Hold → Buy |
| 02/16/2022 | 107.13% | UBS | $325 → $295 | Maintains | Buy |
| 02/16/2022 | 40.43% | Piper Sandler | $330 → $200 | Downgrades | Overweight → Neutral |
| 11/15/2021 | 131.71% | Piper Sandler | $320 → $330 | Maintains | Overweight |
| 01/29/2021 | 100.11% | Raymond James | $275 → $285 | Maintains | Outperform |
| 10/28/2020 | 93.79% | Stifel | $255 → $276 | Maintains | Buy |
| 10/28/2020 | 93.09% | Raymond James | $250 → $275 | Maintains | Outperform |
| 09/02/2020 | 82.56% | Baird | → $260 | Initiates Coverage On | → Outperform |
| 07/29/2020 | 79.05% | Stifel | $245 → $255 | Maintains | Buy |
| 07/29/2020 | 75.54% | Raymond James | $235 → $250 | Maintains | Outperform |
| 04/30/2020 | 72.03% | UBS | $207 → $245 | Maintains | Buy |
| 04/29/2020 | 72.03% | Stifel | $200 → $245 | Maintains | Buy |
| 04/20/2020 | — | Needham | Downgrades | Buy → Hold | |
| 03/02/2020 | 28.49% | Raymond James | → $183 | Upgrades | Market Perform → Outperform |
| 02/20/2020 | 45.34% | UBS | $190 → $207 | Maintains | Buy |
| 02/20/2020 | 41.13% | Needham | $182 → $201 | Maintains | Buy |
| 01/15/2020 | 33.41% | UBS | $180 → $190 | Maintains | Buy |
| 08/01/2019 | 19.37% | Stifel | $165 → $170 | Maintains | Buy |
| 08/01/2019 | 26.39% | UBS | $172 → $180 | Maintains | Buy |
| 05/07/2019 | 12.34% | UBS | $147 → $160 | Maintains | Buy |
| 04/16/2019 | — | BTIG | Downgrades | Buy → Neutral | |
| 12/19/2018 | -15.74% | Piper Sandler | → $120 | Upgrades | Neutral → Overweight |
| 11/28/2018 | -3.81% | UBS | → $137 | Initiates Coverage On | → Buy |
| 10/02/2018 | 1.81% | Stifel | $112 → $145 | Maintains | Buy |
| 09/14/2018 | -2.4% | Needham | → $139 | Initiates Coverage On | → Buy |
| 08/02/2018 | -21.36% | Stifel | $108 → $112 | Maintains | Buy |
| 03/09/2018 | -31.89% | Barclays | → $97 | Initiates Coverage On | → Overweight |
Masimo Questions & Answers
The latest price target for Masimo (NASDAQ: MASI) was reported by Piper Sandler on September 23, 2022. The analyst firm set a price target for $150.00 expecting MASI to rise to within 12 months (a possible 5.32% upside). 14 analyst firms have reported ratings in the last year.
The latest analyst rating for Masimo (NASDAQ: MASI) was provided by Piper Sandler, and Masimo maintained their neutral rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Masimo, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Masimo was filed on September 23, 2022 so you should expect the next rating to be made available sometime around September 23, 2023.
While ratings are subjective and will change, the latest Masimo (MASI) rating was a maintained with a price target of $135.00 to $150.00. The current price Masimo (MASI) is trading at is $142.42, which is within the analyst's predicted range.